天澤信息(300209.SZ):持股5%以上股東中住集團所持2789.65萬股將被司法拍賣
格隆匯12月20日丨天澤信息(300209.SZ)公佈,公司近日通過公開信息查詢獲悉,因被執行人無錫中住集團有限公司(以下簡稱“中住集團”)、孫伯榮、金薇未能履行與申請執行人東吳證券股份有限公司質押式證券回購糾紛一案中已經生效的(2021)蘇05民初1430號民事調解書中所確定的義務。江蘇省蘇州市中級人民法院裁定,拍賣、變賣公司持股5%以上股東中住集團所持公司2789.65萬股股份。上述拍賣活動將於2022年1月20日10時至2022年1月21日10時在阿里巴巴司法拍賣網絡平台上進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.